Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine

Detalhes bibliográficos
Autor(a) principal: Bouça, Bruno
Data de Publicação: 2022
Outros Autores: Roldão, Marisa, Bogalho, Paula, Cerqueira, Luís, Silva-Nunes, José
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/141452
Resumo: Copyright © 2022 Bouça, Roldão, Bogalho, Cerqueira and Silva-Nunes.
id RCAP_0688df9f67b9facf73cac3217981b644
oai_identifier_str oai:run.unl.pt:10362/141452
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 VaccineA Case ReportAdultBNT162 VaccineCOVID-19/prevention & controlCOVID-19 Vaccines/adverse effectsDiabetes Insipidus, Neurogenic/complicationsDiabetes MellitusFemaleHumansHypophysitis/complicationsImmunization/adverse effectsRNA, MessengerSDG 3 - Good Health and Well-beingCopyright © 2022 Bouça, Roldão, Bogalho, Cerqueira and Silva-Nunes.Introduction: Cases of central diabetes insipidus (CDI) have been reported after COVID-19 infection, with hypophysitis being the most likely cause. COVID-19 vaccines potential adverse effects may mimetize some of these complications. Case Report: Woman 37 years old, with rheumatoid arthritis under adalimumab (40 mg twice a month) since December 2018. She was in her usual state of health when she has received the second dose of BNT162b2 mRNA COVID-19 vaccine (June 2021). Seven days later, she started reporting intense thirst and polyuria and consulted her family physician. Blood Analysis: creatinine 0.7 mg/dL, glucose 95mg/dL, Na+ 141mEq/L, K+ 3.9 mEq/L, TSH 3.8 mcUI/L (0.38-5.33), FT4 0.9 ng/dL (0.6-1.1), cortisol 215.4 nmol/L (185-624), ACTH 21.9 pg/mL (6- 48), FSH 4.76 UI/L, LH5.62 UI/L, estradiol 323 pmol/L, IGF1 74.8 ng/mL (88-209), PRL 24.7mcg/L (3.3-26.7) osmolality 298.2 mOs/Kg (250- 325); Urine analysis: volume 10200 mL/24h, osmolality 75 mOs/Kg (300-900), density 1.002. On water restriction test: 0' - Serum osmolality 308.8mOsm/Kg vs. urine osmolality 61.0 mOsm/Kg; 60' - urine osmolality 102 mOsm/Kg; urine osmolality 1 h after desmopressine was 511mOsm/kg. MRI revealed no abnormal signs consistent with hypophysitis except for the loss of the posterior pituitary bright spot on T1 weighted imaging. Diagnosis of CDI was assumed, and started therapy with desmopressine. A report of potential adverse effect was addressed to national health authorities. Conclusion: In hypophysitis MRI often shows loss of posterior pituitary bright spot on T1 weighted imaging, pituitary enlargement or stalk thickening but those findings were not present in this patient. To the best of our knowledge, CDI has never been reported following administration of a COVID-19 vaccine.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNBouça, BrunoRoldão, MarisaBogalho, PaulaCerqueira, LuísSilva-Nunes, José2022-07-05T22:30:46Z2022-05-042022-05-04T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/141452eng1664-2392PURE: 45158072https://doi.org/10.3389/fendo.2022.889074info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:18:52Zoai:run.unl.pt:10362/141452Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:50:00.481378Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine
A Case Report
title Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine
spellingShingle Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine
Bouça, Bruno
Adult
BNT162 Vaccine
COVID-19/prevention & control
COVID-19 Vaccines/adverse effects
Diabetes Insipidus, Neurogenic/complications
Diabetes Mellitus
Female
Humans
Hypophysitis/complications
Immunization/adverse effects
RNA, Messenger
SDG 3 - Good Health and Well-being
title_short Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine
title_full Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine
title_fullStr Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine
title_full_unstemmed Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine
title_sort Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine
author Bouça, Bruno
author_facet Bouça, Bruno
Roldão, Marisa
Bogalho, Paula
Cerqueira, Luís
Silva-Nunes, José
author_role author
author2 Roldão, Marisa
Bogalho, Paula
Cerqueira, Luís
Silva-Nunes, José
author2_role author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Bouça, Bruno
Roldão, Marisa
Bogalho, Paula
Cerqueira, Luís
Silva-Nunes, José
dc.subject.por.fl_str_mv Adult
BNT162 Vaccine
COVID-19/prevention & control
COVID-19 Vaccines/adverse effects
Diabetes Insipidus, Neurogenic/complications
Diabetes Mellitus
Female
Humans
Hypophysitis/complications
Immunization/adverse effects
RNA, Messenger
SDG 3 - Good Health and Well-being
topic Adult
BNT162 Vaccine
COVID-19/prevention & control
COVID-19 Vaccines/adverse effects
Diabetes Insipidus, Neurogenic/complications
Diabetes Mellitus
Female
Humans
Hypophysitis/complications
Immunization/adverse effects
RNA, Messenger
SDG 3 - Good Health and Well-being
description Copyright © 2022 Bouça, Roldão, Bogalho, Cerqueira and Silva-Nunes.
publishDate 2022
dc.date.none.fl_str_mv 2022-07-05T22:30:46Z
2022-05-04
2022-05-04T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/141452
url http://hdl.handle.net/10362/141452
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1664-2392
PURE: 45158072
https://doi.org/10.3389/fendo.2022.889074
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138097239162880

Registros relacionados